利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

886 条记录 (耗时 0.042 秒)

    MACROCYCLIC LRRK2 KINASE INHIBITORS
    63.
    发明申请
    MACROCYCLIC LRRK2 KINASE INHIBITORS 有权
    MACROCYCLIC LRRK2激酶抑制剂

    公开(公告)号：US20150290198A1

    公开(公告)日：2015-10-15

    申请号：US14747882

    申请日：2015-06-23

    申请人： IPSEN PHARMA S.A.S. ,  ONCODESIGN S.A.

    发明人： Jan HOFLACK ,  Petra BLOM

    IPC分类号： A61K31/519 ,  C07D498/18 ,  C07D487/18

    CPC分类号： A61K31/519 ,  C07D487/16 ,  C07D487/18 ,  C07D498/16 ,  C07D498/18 ,  C07D498/22 ,  C07D515/16

    摘要： The present invention relates to novel macrocylic compounds and compositions containing said compounds acting as kinase inhibitors, in particular as inhibitors of LRRK2 (Leucine-Rich Repeat Kinase 2). Moreover, the present invention provides processes for the preparation of the disclosed compounds, as well as methods of using them, for instance as a medicine or diagnostic agent, in particular for the treatment and/or diagnosis of diseases characterized by LRRK2 kinase activity such as neurological disorders including Parkinson's disease and Alzheimer's disease.

    摘要翻译： 本发明涉及新颖的大环化合物和含有所述化合物作为激酶抑制剂的组合物，特别是作为LRRK2（富含亮氨酸重复激酶2）的抑制剂。 此外，本发明提供了制备所公开的化合物的方法，以及使用它们的方法，例如作为药物或诊断剂，特别是用于治疗和/或诊断以LRRK2激酶活性为特征的疾病，例如 神经障碍包括帕金森病和阿尔茨海默病。

    Fluorescent dyes
    64.
    发明申请
    Fluorescent dyes 审中-公开
    荧光染料

    公开(公告)号：US20150259535A1

    公开(公告)日：2015-09-17

    申请号：US14544359

    申请日：2014-12-29

    申请人： AnaSpec Incorporated

    发明人： Zhenjun Diwu ,  Jianheng Zhang ,  Yi Tang ,  Xiang Guobing

    IPC分类号： C09B23/06

    CPC分类号： C09B23/06 ,  C07D487/14 ,  C07D487/22 ,  C07D498/22 ,  C09B23/0066 ,  C09B23/02 ,  G01N33/52 ,  G01N33/533 ,  Y10T436/143333

    摘要： Chemically reactive carbocyanine dyes that are intramolecularly crosslinked between the 1-position and 3′-position, their bioconjugates and their uses are described. 1,3′-crosslinked carbocyanines are superior to those of conjugates of spectrally similar 1,1′-crosslinked or non-crosslinked dyes. The invention includes derivative compounds having one or more benzo nitrogens.

    摘要翻译： 描述了在1位和3'-位之间分子内交联的化学反应性碳菁染料，它们的生物缀合物及其用途。 1,3'-交联的碳氰酸酯优于光谱相似的1,1'-交联或非交联染料的共轭物。 本发明包括具有一个或多个苯并氮的衍生化合物。

    Macrocyclic LRRK2 kinase inhibitors
    66.
    发明授权
    Macrocyclic LRRK2 kinase inhibitors 有权
    大环LRRK2激酶抑制剂

    公开(公告)号：US09096609B2

    公开(公告)日：2015-08-04

    申请号：US14348138

    申请日：2012-09-28

    申请人： IPSEN PHARMA S.A.S. ,  ONCODESIGN S.A.

    发明人： Jan Hoflack ,  Petra Blom

    IPC分类号： C07D487/18 ,  C07D498/18 ,  C07D515/18 ,  C07D498/16 ,  C07D487/16 ,  C07D498/22 ,  C07D515/16

    CPC分类号： A61K31/519 ,  C07D487/16 ,  C07D487/18 ,  C07D498/16 ,  C07D498/18 ,  C07D498/22 ,  C07D515/16

    摘要： The present invention relates to novel macrocylic compounds and compositions containing said compounds acting as kinase inhibitors, in particular as inhibitors of LRRK2 (Leucine-Rich Repeat Kinase 2). Moreover, the present invention provides processes for the preparation of the disclosed compounds, as well as methods of using them, for instance as a medicine or diagnostic agent, in particular for the treatment and/or diagnosis of diseases characterized by LRRK2 kinase activity such as neurological disorders including Parkinson's disease and Alzheimer's disease.

    摘要翻译： 本发明涉及新颖的大环化合物和含有所述化合物作为激酶抑制剂的组合物，特别是作为LRRK2（富含亮氨酸重复激酶2）的抑制剂。 此外，本发明提供了制备所公开的化合物的方法，以及使用它们的方法，例如作为药物或诊断剂，特别是用于治疗和/或诊断以LRRK2激酶活性为特征的疾病，例如 神经障碍包括帕金森病和阿尔茨海默病。

    POLYMORPHIC FORMS ALPHA, BETA AND GAMMA OF RIFAXIMIN
    68.
    发明申请
    POLYMORPHIC FORMS ALPHA, BETA AND GAMMA OF RIFAXIMIN 审中-公开
    多聚体形式的阿尔法，BETA和游戏的RIFAXIMIN

    公开(公告)号：US20150175627A1

    公开(公告)日：2015-06-25

    申请号：US14457909

    申请日：2014-08-12

    申请人： ALFA WASSERMANN S.P.A.

    发明人： Giuseppe Claudio VISCOMI ,  Manuela CAMPANA ,  Dario BRAGA ,  Donatella CONFORTINI ,  Vincenzo CANNATA ,  Paolo RIGHI ,  Goffredo ROSINI ,  Denis Severini

    IPC分类号： C07D498/22

    CPC分类号： C07D498/22 ,  C07B2200/13 ,  C07D491/22

    摘要： Crystalline polymorphous forms of rifaximin (INN) antibiotic named rifaximin α and rifaximin β, and a poorly crystalline form named rifaximin γ, useful in the production of medicinal preparations containing rifaximin for oral and topical use and obtained by means of a crystallization carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a determinate temperature and for a determinate period of time, followed by a drying carried out under controlled conditions until reaching a settled water content in the end product, are the object of the invention.

    摘要翻译： 结晶多形态的利福昔明（INN）抗生素名为利福昔明α和利福昔明，并且结晶形式名为利福昔明γ，可用于生产含有利福昔明用于口服和局部使用的药物制剂，并通过结晶进行 将生的利福昔明热溶解在乙醇中，并通过在确定的温度下加入水并在一定的时间内引起产物的结晶，然后在受控条件下进行干燥，直到达到沉淀的含水量 最终产品是本发明的目的。